Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping

Mar 24 2022

• By Derrick Gingery

auto-injector — Proposed legislation would change the interchangeability system for biosimilars of Humira and other biologics going forward. • Source: Alamy

Related Content

US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening

Sep 11 2021

Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies

Oct 18 2021

US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?

Aug 19 2018

Clinical Trial Diversity Measures Primed For Inclusion In US FDA User Fee Legislation

Mar 18 2022

Accelerated Approval Reform Proposals Worry Industry: ‘Science Doesn’t Move The Same Way’

Mar 18 2022

Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown

Mar 09 2022

FDA Shortage Notification Mandate May Not Extend To Biologics

Dec 24 2012

FDA ‘Encouraging Evergreening’ With Strength Definition – Boehringer Ingelheim

Dec 21 2020

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Amgen, Inc.

Alvotech

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Biosimilars Legislation Review Pathway Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window